Longitudinal management with crossmatch-compatible platelets for refractory patients: Alloimmunization, response to transfusion, and clinical outcomes (CME)

Transfusion

Volumn 52, Issue 10, 2012, Pages 2146-2154

  Wiita, Arun P ^a   Nambiar, Ashok ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868300229     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03593.x     Document Type: Article

References (26)

1. Hod E, Schwartz J,. Platelet transfusion refractoriness. Br J Haematol 2008; 142: 348-60.
2. Sacher RA, Kickler TS, Schiffer CA, Sherman LA, Bracey AW, Shulman IA,. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003; 127: 409-14.
3. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R,. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105: 4106-14.
4. Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD,. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993; 81: 3428-34.
5. Rebulla P,. A mini-review on platelet refractoriness. Haematologica 2005; 90: 247-53.
6. Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RTJ,. Wintrobe's clinical hematology. 12th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2009.
7. Delaflor-Weiss E, Mintz PD,. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000; 14: 180-96.
8. Moroff G, Garratty G, Heal JM, MacPherson BR, Stroncek D, Huang ST, Ho W, Petz LD, Leach MF, Lennon SS, Rowe JM, Saleh MN, Arndt P, Foley K, Masel D, Postoway N,. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992; 32: 633-40.
9. Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M,. Rossi's principles of transfusion medicine. 4th ed. Bethesda (MD): American Association of Blood Banks Press; 2009.
10. Nambiar A, Duquesnoy RJ, Adams S, Zhao Y, Oblitas J, Leitman S, Stroncek D, Marincola F,. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107: 1680-7.
11. Duquesnoy RJ,. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008; 48: 221-7.
12. Pai SC, Lo SC, Lin Tsai SJ, Chang JS, Lin DT, Lin KS, Lin LI,. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50: 2318-27.
13. Freedman J, Gafni A, Garvey MB, Blanchette V,. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion 1989; 29: 201-7.
14. Rachel JM, Summers TC, Sinor LT, Plapp FV,. Use of a solid phase red blood cell adherence method for pretransfusion platelet compatibility testing. Am J Clin Pathol 1988; 90: 63-8.
15. Gelb AB, Leavitt AD,. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997; 37: 624-30.
16. Petz LD, Garratty G, Calhoun L, Clark BD, Terasaki PI, Gresens C, Gornbein JA, Landaw EM, Smith R, Cecka JM,. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40: 1446-56.
17. O'Connell BA, Schiffer CA,. Donor selection for alloimmunized patients by platelet crossmatching of random-donor platelet concentrates. Transfusion 1990; 30: 314-7.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
19. Heddle NM, Wu C, Vassallo R, Carey P, Arnold D, Lozano M, Pavenski K, Sweeney J, Stanworth S, Liu Y, Traore A, Barty R, Tinmouth A,; BEST Collaborative. Adjudicating bleeding events in a platelet dose study: impact on outcome results and challenges. Transfusion 2011; 51: 2304-10.
20. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough JJ, McIntyre RE, Powell BL, Rainey JM, Rowley SD, Rebulla P, Troner MB, Wagnon AH,. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.
21. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR,. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402-7.
22. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-9.
23. Lee EJ, Schiffer CA,. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987; 70: 1727-9.
24. Murphy MF, Metcalfe P, Ord J, Lister TA, Waters AH,. Disappearance of HLA and platelet-specific antibodies in acute leukaemia patients alloimmunized by multiple transfusions. Br J Haematol 1987; 67: 255-60.
25. Friedberg RC, Donnelly SF, Mintz PD,. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994; 34: 215-20.
26. Heal JM, Blumberg N, Masel D,. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70: 23-30.